Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Increased bone marrow CD56bright natural killer cells at 30 days after allogeneic stem cell transplantation associated with adverse patient outcome

Bone Marrow Transplantation volume 54, pages 924–927 (2019)Cite this article

Subjects

Immune reconstituion (IR) study by flow cytometric analysis has the advantage of being widely available in clinical laboratories and allows for evaluating variety of lymphocyte subsets with a small amount of bone marrow samples [1,2,3,4,5,6,7,8]. The aim of the current study was to retrospectively evaluate whether the reconstitution of lymphocytes subsets in bone marrow of acute myeloid leukemia (AML) patients after allogeneic stem cell transplant (Allo-SCT) correlated with post-transplant outcomes.

We retrospectively evaluated 48 adult AML patients who underwent first peripheral blood or bone marrow Allo-SCT during biopsy-proven complete remission at Florida Hospital between 2012 and 2015. Patients who died within 1 month of transplant were excluded since the bone marrow aspirate at 30 days could not be assessed. All the included patients had bone marrow aspirate and biopsy samples obtained at 30 days (D + 30) after Allo-SCT. The AML patients were stratified into favorable, intermediate, and adverse risk group according to 2017 ELN genetic risk stratification [9]. This retrospective study was approved by Florida Hospital institutional review board.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Pavletic ZS, Joshi SS, Pirruccello SJ, Tarantolo SR, Kollath J, Reed EC, et al. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant. 1998;21:33–41.

    Article  CAS  Google Scholar 

  2. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, et al. Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. Leukemia. 2003;17:1865–70.

    Article  CAS  Google Scholar 

  3. Novitzky N, Davison GM. Immune reconstitution following hematopoietic stem-cell transplantation. Cytotherapy. 2001;3:211–20.

    Article  CAS  Google Scholar 

  4. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood. 2010;115:3861–8. https://doi.org/10.1182/blood-2009-12-234096

    Article  CAS  PubMed  Google Scholar 

  5. Danby R, Rocha V. Improving engraftment and immune reconstitution in umbilical cord blood transplantation. Front Immunol. 2014;5:68.

    Article  Google Scholar 

  6. Martin PS, Li S, Nikiforow S, Alyea EP III, Antin JH, Armand P, et al. Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica. 2016;101:499–505.

    Article  CAS  Google Scholar 

  7. Toubert A, Glauzy S, Douay C, Clave E. Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: never say never again. Tissue Antigens. 2012;79:83–89.

    Article  CAS  Google Scholar 

  8. Ogonek J, Kralj Juric M, Ghimire S, Varanasi PR, Holler E, Greinix H, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:507.

    Article  Google Scholar 

  9. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

    Article  Google Scholar 

  10. Nguyen S, Dhedin N, Vernant JP, Kuentz M, Al Jijakli A, Rouas-Freiss N, et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood. 2005;105:4135–42.

    Article  CAS  Google Scholar 

  11. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood. 1996;88:2775–9.

    CAS  PubMed  Google Scholar 

  12. Shenoy S, Mohanakumar T, Todd G, Westhoff W, Dunnigan K, Adkins DR, et al. Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant. 1999;23:335–46.

    Article  CAS  Google Scholar 

  13. Buhlmann L, Buser AS, Cantoni N, Gerull S, Tichelli A, Gratwohl A, et al. Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011;46:1357–62.

    Article  CAS  Google Scholar 

  14. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113:726–32.

    Article  CAS  Google Scholar 

  15. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med. 2012;367:805–16.

    Article  CAS  Google Scholar 

  16. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105:4878–84.

    Article  CAS  Google Scholar 

  17. Chang YJ, Zhao XY, Huang XJ. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant. 2008;14:323–34.

    Article  Google Scholar 

  18. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331:44–49.

    Article  CAS  Google Scholar 

  19. Waggoner SN, Reighard SD, Gyurova IE, Cranert SA, Mahl SE, Karmele EP, et al. Roles of natural killer cells in antiviral immunity. Curr Opin Virol. 2016;16:15–23.

    Article  CAS  Google Scholar 

  20. Eissens DN, Spanholtz J, van der Meer A, van Cranenbroek B, Dolstra H, Kwekkeboom J, et al. Defining early human NK cell developmental stages in primary and secondary lymphoid tissues. PLoS ONE. 2012;7:e30930.

    Article  CAS  Google Scholar 

  21. Michel T, Poli A, Cuapio A, Briquemont B, Iserentant G, Ollert M, et al. Human CD56bright NK cells: an update. J Immunol. 2016;196:2923–31.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Ren Ching Wang, Shahram Mori

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Florida Hospital, Orlando, FL, USA

    Ren Ching Wang, Debbie Dickman, David Ward & Chun-Che Chang

  2. Department of Pathology and Laboratory Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

    Ren Ching Wang

  3. Blood and Marrow Transplant Center, Florida Hospital, Orlando, FL, USA

    Shahram Mori, Juan Carlos Varela, Rushang Patel & Steven C. Goldstein

  4. Research Analytics Institute, Florida Hospital, Orlando, FL, USA

    Xiang Zhu

  5. Department of Pathology, College of Medicine, University of Central Florida, Orlando, FL, USA

    Chun-Che Chang

Authors
  1. Ren Ching Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shahram Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiang Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Juan Carlos Varela
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Debbie Dickman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rushang Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. David Ward
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Steven C. Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chun-Che Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shahram Mori.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, R.C., Mori, S., Zhu, X. et al. Increased bone marrow CD56bright natural killer cells at 30 days after allogeneic stem cell transplantation associated with adverse patient outcome. Bone Marrow Transplant 54, 924–927 (2019). https://doi.org/10.1038/s41409-018-0407-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0407-y

Search

Advanced search

Quick links